Home › Research › Getting a diagnosis
The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management
Atri A.. The Medical clinics of North America, 2019-03-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease (AD) care requires timely diagnosis and multidisciplinary management. Evaluation involves structured patient and caregiver history and symptom-function reviews, examination, and testing (laboratory and neuroimaging) to delineate impairment level, determine the cognitive-behavioral syndrome, and diagnose cause. Clinical biomarkers are available to aid high confidence in etiologic diagnosis. Management uses psychoeducation, shared goal setting, and patient-caregiver dyad decision making. When combined, pharmacologic and nonpharmacologic therapies mitigate symptoms and reduce clinical progression and care burden. AD biopathologic processes develop over decades before symptoms manifest; this period is increasingly targeted in research as an opportunity to best delay or prevent AD dementia.
What this study adds
Evidence grade: Low
This is a narrative review. This review states that Alzheimer's disease management uses psychoeducation, shared goal setting, and patient-caregiver dyad decision making, and that combined pharmacologic and nonpharmacologic therapies mitigate symptoms and reduce clinical progression and care burden. Alzheimer's disease biopathologic processes develop over decades before symptoms manifest, and this period is increasingly targeted in research as an opportunity to best delay or prevent Alzheimer's disease dementia.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Atri, A. (2019). The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management. The Medical clinics of North America. https://doi.org/10.1016/j.mcna.2018.10.009
Vancouver
Atri A. The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management. The Medical clinics of North America. 2019. doi:10.1016/j.mcna.2018.10.009. PMID: 30704681.
BibTeX
@article{atri2019-30704681,
author = {Atri, A.},
title = {{The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management}},
journal = {The Medical clinics of North America},
year = {2019},
doi = {10.1016/j.mcna.2018.10.009},
pmid = {30704681},
url = {https://doi.org/10.1016/j.mcna.2018.10.009}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Evaluation involves structured patient and caregiver history and symptom-function reviews, examination, and testing (laboratory and neuroimaging) to delineate impairment level, determine the cognitive-behavioral syndrome, and diagnose cause.
- Clinical biomarkers are available to aid high confidence in etiologic diagnosis.
- Management uses psychoeducation, shared goal setting, and patient-caregiver dyad decision making.
- When combined, pharmacologic and nonpharmacologic therapies mitigate symptoms and reduce clinical progression and care burden.
- AD biopathologic processes develop over decades before symptoms manifest; this period is increasingly targeted in research as an opportunity to best delay or prevent AD dementia.
Why it matters
This review states that Alzheimer's disease management uses psychoeducation, shared goal setting, and patient-caregiver dyad decision making, and that combined pharmacologic and nonpharmacologic therapies mitigate symptoms and reduce clinical progression and care burden. Alzheimer's disease biopathologic processes develop over decades before symptoms manifest, and this period is increasingly targeted in research as an opportunity to best delay or prevent Alzheimer's disease dementia.
New to this subject? Start with our plain-English guide: Getting a diagnosis →
Study details
- Evidence strengthLow
How this study scored 54/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Medical clinics of North America) |
| Journal's citation record | 2 / 4 | Medical Clinics of North America: journal h-index 161 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 621 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 69.0 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 5 / 6 | Cited 34.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 13 other studies in this library |
| Still being cited | 4 / 4 | Cited 301 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Alireza Atri: h-index 49 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30704681) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.mcna.2018.10.009
- PubMed: 30704681
- Original source →
- Free full text: Medical Clinics of North America →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 47.
Later studies that cite this one
13 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Getting a diagnosis from nearby years
Also in Getting a diagnosis
141 studies in the library are filed under Getting a diagnosis with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Getting a diagnosis hub.